NASDAQ$CRVO
Diffusion Pharmaceuticals Inc · Q3 2023 earnings
Q3 2023 earnings · · Investor relations
Briefing
CervoMed reported financial results and business highlights, including dosing the first patient in Phase 2b RewinD-LB study and completing a reverse merger to begin trading on Nasdaq.
CervoMed reported a net income of $2.2 million for the third quarter of 2023, driven by a noncash gain from the conversion of convertible notes upon the merger. The company's cash position is expected to fund operations through the end of 2024, with key data expected from the RewinD-LB trial.
- Dosed first patient in Phase 2b RewinD-LB study evaluating neflamapimod in patients with dementia with Lewy bodies (DLB).
- Multiple peer-reviewed journal publications and a conference presentation inform on the potential of neflamapimod in DLB and probability of success in optimized RewinD-LB study.
- Completed reverse merger; company now publicly traded on Nasdaq (“CRVO”).
- CervoMed has cash runway through the end of 2024, by which time the topline primary efficacy results from the Phase 2b RewinD-LB study are expected to be available.
Headline financials
Revenue & EPS history
CervoMed · Revenue · Quarterly
$1.53M
Forward guidance
CervoMed anticipates completing patient enrollment into the RewinD-LB Phase 2b clinical study in DLB in the first half of 2024 and reporting initial data from placebo-controlled portion of the RewinD-LB study during the second half of 2024
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q3 2023
+0.4%
Avg return
Earnings day
+177.7%
Avg return
5 days after
-10.0%
Avg return
30 days after
31%
20 / 65 earnings
Positive
+39.3%
Q1 2020
Best reaction
-27.6%
Q3 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -8.5% | — | — | |
| Q4 2025 | +5.1% | -6.7% | -7.4% | |
| Q3 2025 | -0.3% | +11.0% | +25.3% | |
| Q2 2025 | +5.5% | +3.2% | +12.5% | |
| Q1 2025 | +0.0% | -4.1% | -17.3% | |
| Q4 2024 | +3.2% | +57.9% | +8.3% | |
| Q3 2024 | -7.6% | -11.3% | -84.1% | |
| Q2 2024 | +33.0% | +61.9% | +39.3% | |
| Q1 2024 | -1.4% | -20.1% | -23.0% | |
| Q4 2023 | -4.9% | -12.0% | +3.7% | |
| Q3 2023 | -2.6% | +0.2% | -10.6% | |
| Q2 2023 | -1.1% | +9.5% | +10.4% | |
| Q1 2023 | -5.4% | -1.7% | -11.3% | |
| Q4 2022 | -8.7% | -12.7% | -27.1% | |
| Q3 2022 | +21.4% | +22.0% | +28.6% | |
| Q2 2022 | -2.0% | -1.4% | -7.1% | |
| Q1 2022 | +18.6% | +25.5% | +25.5% | |
| Q4 2021 | -3.7% | +0.0% | -43.0% | |
| Q3 2021 | -6.7% | -4.4% | -15.6% | |
| Q2 2021 | -7.0% | -14.0% | -3.5% | |
| Q1 2021 | +0.0% | +6832.2% | +13.2% | |
| Q4 2020 | +4.9% | +4.9% | -99.1% | |
| Q3 2020 | -10.1% | -20.3% | -6.3% | |
| Q2 2020 | -0.9% | -1.8% | -22.7% | |
| Q1 2020 | +39.3% | +121.3% | +77.0% | |
| Q4 2019 | -8.8% | -17.6% | +17.6% | |
| Q3 2019 | -27.6% | -69.7% | -25.0% | |
| Q2 2019 | -0.9% | -3.7% | -10.6% | |
| Q1 2019 | -4.9% | -3.8% | -29.6% | |
| Q4 2018 | +3.8% | -4.3% | -33.6% | |
| Q3 2018 | +0.0% | -12.1% | -41.8% | |
| Q2 2018 | +2.8% | +13.9% | +11.1% | |
| Q4 2017 | -3.6% | -11.3% | -1.9% | |
| Q1 2018 | -3.6% | +1.8% | +1.8% | |
| Q3 2017 | -3.6% | -1.5% | +3.6% | |
| Q2 2017 | -7.7% | +0.0% | +12.5% | |
| Q4 2016 | -0.6% | +3.1% | -15.8% | |
| Q1 2017 | -0.6% | +3.1% | -15.8% | |
| Q3 2016 | -3.8% | -4.8% | -40.0% | |
| Q2 2016 | +0.0% | +0.0% | -90.0% | |
| Q1 2016 | +11.1% | — | — | |
| Q4 2015 | -6.4% | — | — | |
| Q3 2015 | -9.1% | — | — | |
| Q2 2015 | +1.2% | — | — | |
| Q1 2015 | -2.0% | — | — | |
| Q4 2014 | -7.1% | — | — | |
| Q3 2014 | -1.1% | — | — | |
| Q2 2014 | +4.5% | — | — | |
| Q1 2014 | -3.2% | — | — | |
| Q4 2013 | +0.0% | — | — | |
| Q3 2013 | +0.0% | — | — | |
| Q2 2013 | +0.0% | — | — | |
| Q1 2013 | +0.0% | — | — | |
| Q4 2012 | +18.8% | — | — | |
| Q3 2012 | +4.8% | — | — | |
| Q2 2012 | -2.6% | — | — | |
| Q1 2012 | +0.0% | — | — | |
| Q4 2011 | +8.0% | — | — | |
| Q3 2011 | -11.5% | — | — | |
| Q2 2011 | +7.1% | — | — | |
| Q1 2011 | +5.5% | — | — | |
| Q4 2010 | +1.6% | — | — | |
| Q3 2010 | +19.0% | — | — | |
| Q2 2010 | -12.0% | — | — | |
| Q1 2010 | +0.0% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro